Recombinant interferon-α therapy in patients with follicular lymphoma

Cancer

Volumn 82, Issue 10, 1998, Pages 1821-1830

  Ozer, Howard ^a   Wiernik, Peter H ^b   Giles, Francis ^c   Tendler, Craig ^d  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Combination chemotherapy; Hematology; Interferon ; Non Hodgkin's lymphoma

Indexed keywords

BLEOMYCIN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; METHOTREXATE; PREDNISONE; PROCARBAZINE; RECOMBINANT ALPHA INTERFERON; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; TENIPOSIDE; VINCRISTINE;

ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; FOLLICULAR LYMPHOMA; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MAINTENANCE THERAPY; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; HUMANS; INTERFERON TYPE I, RECOMBINANT; LYMPHOMA, FOLLICULAR; REMISSION INDUCTION;

EID: 2642706652     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980515)82:10<1821::AID-CNCR3>3.0.CO;2-Q     Document Type: Review

References (57)

1. Cancer Facts & Figures - 1997. Atlanta, GA: American Cancer Society, 1997.
2. Rosenberg SA, Berard CW, Brown BW, Burke J, Dorfman RF, et al. Non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas. Summary and description of a working formulation for clinical usage. Cancer 1982;49:2112-35.
3. Jaffee ES. Pathology of malignant lymphomas in neoplastic diseases of the blood. Wiernik PH, et al., editors. Neoplastic diseases of the blood. 2nd edition. New York: Churchill Livingstone, 1991:634.
4. Harris NL, Nadler LM, Bhan AK. Immunohistologic characterization of two malignant lymphomas of germinal center type (centroblastic/centrocytic and centrocytic) with monoclonal antibodies. Follicular and diffuse lymphomas of small-cleaved-cell type are related but distinct entities. Am J Pathol 1984;117:262-72.
5. Tsujimoto Y, Cossman J, Jaffe E, Croce CM. Involvement of the bcl-2 gene in human follicular lymphoma. Science 1985;228:1440-3.
6. Korsmeyer SJ. Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 1992;80:879-86.
7. Portlock CS. Management of the low-grade non-Hodgkin's lymphomas. Semin Oncol 1990;17:51-9.
8. Bastion Y, Berger F, Bryon PA, Felman P, Ffrench M, Coiffier B. Follicular lymphomas: assessment of prognostic factors in 127 patients followed for 10 years. Ann Oncol 1991;2 (Suppl 2):123-9.
9. Solal-Celigny P, Lepage E, Brousse N, Reyes F, Haioun C, Leporrier M, et al. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d'etude des lymphomes de l'adulte. N Engl J Med 1993;329:1608-14.
10. Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med 1984;311:1471-5.
11. Young RC, Longo DL, Glatstein E, Ihde DC, Jaffe ES, DeVita VT Jr. The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. Semin Hematol 1988;25:11-6.
12. Brice P, Bastion Y, Lepage E, Brousse N, Haioun C, Moreau P, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 1997;15:1110-7.
13. Coiffier B. Interferon alpha-recombinant in the treatment of follicular lymphoma patients [editorial]. Ann Oncol 1993;4:182-3.
14. Romaguera JE, McLaughlin P, North L, Dixon D, Silvermintz KB, Garnsey LA, et al. Multivariate analysis of prognostic factors in stage IV follicular low-grade lymphoma: a risk model. J Clin Oncol 1991;9:762-9.
15. Gallagher CJ, Gregory WM, Jones AE, Stansfeld AG, Richards MA, Dhaliwal HS, et al. Follicular lymphoma: prognostic factors for response and survival. J Clin Oncol 1986;4:1470-80.
16. Kimby E, Bjorkholm M, Gahrton G, Glimelius B, Hagbcrg H, Johansson B, et al. Chlorambucil/prednisone VS. CHOP in symptomatic low-grade non-Hodgkin's lymphomas: a randomized trial from the lymphoma group of central Sweden. Ann Oncol 1994;5:67-71.
17. Ezdinli EZ, Anderson JR, Melvin F, Glick JH, Davis TE, O'Connell MJ. Moderate versus aggressive chemotherapy of nodular lymphocytic poorly differentiated lymphoma. J Clin Oncol 1985;3:769-75.
18. Glick JH, Barnes JM, Ezdinli EZ, Berard CW, Orlow EL, Bennett JM. Nodular mixed lymphoma: results of a randomized trial failing to confirm prolonged disease-free survival with COPP chemotherapy. Blood 1981;58:920-5.
19. Steward WP, Crowther D, McWilliam LJ, Jones JM, Deakin DP, Todd ID, et al. Maintenance chlorambucil after CVP in the management of advanced stage, low-grade histologic type non-Hodgkin's lymphoma. A randomized prospective study with an assessment of prognostic factors. Cancer 1988;61:441-7.
20. Kalter S, Holmes L, Cabanillas F. Long-term results of treatment of patients with follicular lymphomas. Hematol Oncol 1987;5:127-38.
21. Dana BW, Dahlberg S, Nathwani BN, Chase E, Coltman C, Miller TP, et al. Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy. J Clin Oncol 1993;11:644-51.
22. Sullivan KM, Nieman PE, Kadin ME, Dahlberg S, Farewell VT, Rudolph RH. Combined modality therapy of advanced non-Hodgkin's lymphoma: an analysis of remission duration and survival in 95 patients. Blood 1983;62:51-61.
23. Anderson KC, Skarin AT, Rosenthal DS, MacIntyre JM, Pinkus GS, Case DC Jr., et al. Combination chemotherapy for advanced non-Hodgkin's lymphomas other than diffuse histiocytic or undifferentiated histologies. Cancer Treat Rep 1984;68:1343-50.
24. Jones SE, Grozea PN, Metz EN, Haut A, Stephens RL, Morrison FS, et al. Superiority of adriamycin-containing combination chemotherapy in the treatment of diffuse lymphoma. A southwest oncology group study. Cancer 1979;43:417-25.
25. Andersen JW, Smalley RV. Interferon alfa plus chemotherapy for non-Hodgkin's lymphoma: five-year follow-up [letter]. N Engl J Med 1993;329:1821-2.
26. Bishop JF, Wiernik PH, Wesley MN, Kaplan RS, Diggs CH, Barcos MP, et al. A randomized trial of high dose cyclophosphamide, vincristine, and prednisone plus or minus doxorubicin (CVP versus CAVP) with long-term follow-up in advanced non-Hodgkin's lymphoma. Leukemia 1987;1:508-13.
27. Smalley RV, Andersen JW, Hawkins MJ, Bhide V, O'Connell MJ, Oken MM, et al. Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma. N Engl J Med 1992;327:1336-41.
28. O'Connell MJ, Colgan JP, Oken MM, Ritts RE Jr., Kay NE, Itri LM. Clinical trial of recombinant leukocyte α interferon as initial therapy for favorable histology non-Hodgkin's lymphomas and chronic lymphocytic leukemia. An Eastern Cooperative Oncology Group pilot study. J Clin Oncol 1986;4:128-36.
29. Foon KA, Sherwin SA, Abrams PG, Longo DL, Fer MF, Stevenson HC, et al. Treatment of advanced non-Hodgkin's lymphoma with recombinant leukocyte α interferon. N Engl J Med 1984;311:1148-52.
30. Wagstaff J, Loynds P, Crowther D. A phase II study of human rDNA alpha-2 interferon in patients with low grade non-Hodgkin's lymphoma. Cancer Chemother Pharmacol 1986;18:54-8.
31. Leavitt RD, Ratanatharathorn V, Ozer H, Ultmann JE, Portlock C, Myers JW, et al. Alfa-2b interferon in the treatment of Hodgkin's disease and non-Hodgkin's lymphoma. Semin Oncol 1987;14:18-23.
32. Wadler S, Schwartz EL. Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res 1990; 50:3473-86.
33. Gresser I, Maury C, Tovey M. Efficacy of combined interferon cyclophosphamide therapy after diagnosis of lymphoma in AKR mice. Eur J Cancer 1978;14:97-9.
34. Balkwill FR, Moodie EM. Positive interactions between human interferon and cyclophosphamide or adriamycin in a human tumor model system. Cancer Res 1984;44:904-8.
35. Rohatiner AZ, Richards MA, Barnett MJ, Stansfeld AG, Lister TA. Chlorambucil and interferon for low grade non-Hodgkin's lymphoma. Br J Cancer 1987;55:225-6.
36. Ozer H, Anderson JR, Peterson BA, Budman DR, Henderson ES, Bloomfield CD, et al. Combination trial of subcutaneous interferon alfa-2b and oral cyclophosphamide in favorable histology, non-Hodgkin's lymphoma. Invest New Drugs 1987;5:S27-S33.
37. Chisesi T, Capnist G, Vespignani M, Dini E. The role of interferon alfa-2b and chlorambucil in the treatment of non-Hodgkin's lymphoma. Cancer Treat Rev 1988;15:27-33.
38. Price CG, Rohatiner AZ, Steward W, Deakin D, Bailey N, Norton A, et al. Interferon-alpha 2b in the treatment of follicular lymphoma: preliminary results of a trial in progress. Ann Oncol 1991;2:141-5.
39. Rohatiner A, Crowther D, Radford J, Deakin D, Earl H, Price C, et al. The role of interferon in follicular lymphoma [abstract). Proc Am Soc Clin Oncol 1996;15:418.
40. Peterson BA, Petroni G, Oken MM, Ozer H. Cyclophosphamide versus cyclophosphamide plus interferon alfa-2b in follicular low-grade lymphomas: a preliminary report of an intergroup trial (CALGB 8691 and EST 7486) [abstract]. Proc Am Soc Clin Oncol 1993;12:366.
41. Peterson BA, Petroni GR, Oken MM, Johnson JL, Barcos M, Cooper MR. Cyclophosphamide versus cyclophosphamide plus interferon alfa-2b in follicular low-grade lymphomas: an intergroup phase III trial (CALGB 8691 and EST 7486) [abstract]. Proc Am Soc Clin Oncol 1997;16:14a.
42. Solal-Celigny P, Lepage E, Brousse N, Tertian G, Thyss A, Reman O, et al. A doxorubicin containing regimen with or without interferon alpha-2b (IFN-α2b) in advance follicular lymphomas. Final analysis of survival, toxicity and quality of life of the GELF86 trial [abstract]. Blood 1996;88:453a.
43. Glasziou PP, Simes RJ, Gelber RD. Quality adjusted survival analysis. Stat Med 1990;9:1259-76.
44. Cole BF, Solal-Céligny P, LePage E. Interferon alpha for the treatment of advanced follicular lymphoma: an analysis of quality-of-life-adjusted survival [abstract]. Blood 1995; 86:440a.
45. McLaughlin P, Cabanillas F, Hagemeister FB, Swan F Jr., Romaguera JE, Taylor S, et al. Chop-bleo plus interferon for stage IV low-grade lymphoma. Ann Oncol 1993;4:205-11.
46. Hagenbeek A, Carde P, Somers R, Thomas J, De Bock R, Van Hoof A, et al. Interferon-alfa-2a VS control as maintenance therapy for low grade non-Hodgkin's lymphoma: results from a prospective randomized clinical trial. Proc Am Soc Clin Oncol 1995;14:386.
47. Hiddemann W, Unterhalt M, Koch P, Nahler M, Herrmann R. New aspects in the treatment of advanced low-grade non-Hodgkin's lymphomas: prednimustine/mitoxantrone versus cyclophosphamide/vincristine/prednisone followed by interferon alfa versus observation only - a preliminary update of the German Low-Grade Lymphoma Study Group. Semin Hematol 1994;31:32-5.
48. Unterhalt M, Herrmann R, Nahler M, Trümper L, Bodenstein H, Landys K, et al. Significant prolongation of disease free survival in advanced low grade non-Hodgkin's lymphomas (NHL) by interferon alfa maintenance [abstract]. Blood 1995;86:439a.
49. Unterhalt M, Herrmann R, Tiemann M, Parwaresch R, Stein H, Trumper L, et al. Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. German Low-Grade Lymphoma Study Group. Leukemia 1996;10:836-43.
50. Avilés A, Duque G, Talavera A, Guzman R. Interferon alpha 2b as maintenance therapy in low grade malignant lymphoma improves duration of remission and survival. Leuk Lymphoma 1996;20:495-9.
51. Horning SJ. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 1993;20:75-88.
52. Metter GE, Nathwani BN, Burke JS, Winberg CD, Mann RB, Barcos M, et al. Morphological subclassification of follicular lymphoma: variability of diagnoses among hematopathologists, a collaborative study between the Repository Center and Pathology Panel for Lymphoma Clinical Studies. J Clin Oncol 1985;3:25-38.
53. Nathwani BN, Metter GE, Miller TP, Burke JS, Mann RB, Barcos M, et al. What should be the morphologic criteria for the subdivision of follicular lymphomas? Blood 1986;68:837-45.
54. Weiss RB. Miscellaneous toxicities. In: DeVita VT Jr., Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. 5th edition. Philadelphia: Lippincott-Raven Publishers, 1997:2796-806.
55. Solal-Celigny P, Brice P, Brousse N, Caspard H, Bastion Y, Haioun C, et al. Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: a multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 1996;14:514-9.
56. Borden EC. Interferons. In: Holland JF Jr., Bast RC, Morton DL, Frei E, Kufe DW, Weichselbaum RR, editors. Cancer medicine. 4th edition. Baltimore: Williams and Wilkins, 1997:1199-212.
57. Quesada JR, Talpaz M, Rios A, Kurzrock R, Gutterman JU. Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol 1986;4:234-43.